Methods of treatment of periodontal disease
First Claim
Patent Images
1. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein is encoded by a nucleic acid that hybridizes under stringent hybridization conditions (hybridization at 65°
- C. in 6×
SSC, 0.01M EDTA, 5×
Denhardt'"'"'s solution, 0.5% SDS, 100 μ
g/ml denatured salmon sperm DNA, labelled DNA probe;
washing at 65°
C. in 0.2×
SSC, 0.1×
SDS) to the complement of SEQ ID NO;
1 or SEQ ID NO;
3, wherein the encoded BMP protein has the ability to induce formation of cartilage or bone or both.
0 Assignments
0 Petitions
Accused Products
Abstract
Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
-
Citations
8 Claims
-
1. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein is encoded by a nucleic acid that hybridizes under stringent hybridization conditions (hybridization at 65°
- C. in 6×
SSC, 0.01M EDTA, 5×
Denhardt'"'"'s solution, 0.5% SDS, 100 μ
g/ml denatured salmon sperm DNA, labelled DNA probe;
washing at 65°
C. in 0.2×
SSC, 0.1×
SDS) to the complement of SEQ ID NO;
1 or SEQ ID NO;
3, wherein the encoded BMP protein has the ability to induce formation of cartilage or bone or both. - View Dependent Claims (2)
- C. in 6×
-
3. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence of SEQ ID NO:
- 2 or SEQ ID NO;
4.
- 2 or SEQ ID NO;
-
4. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises amino acids 299–
- 396 of SEQ ID NO;
4.
- 396 of SEQ ID NO;
-
5. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises amino acids 32–
- 129 of SEQ ID NO;
2.
- 129 of SEQ ID NO;
-
6. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:
- 1 or SEQ ID NO;
3.
- 1 or SEQ ID NO;
-
7. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by nucleotides 1–
- 387 of SEQ ID NO;
1.
- 387 of SEQ ID NO;
-
8. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by nucleotides 356–
- 1543 of SEQ ID NO;
3.
- 1543 of SEQ ID NO;
Specification